LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
=== Crime === According to the City of Raleigh Crime Statistical Overview, in 2022, the Raleigh Police Department and other agencies in the city reported 1,797 incidents of violent crime and 11,537 incidents of property crime – making property crime about 24% higher than the national average and violent crime about 2% higher than the national average. Of the violent crimes reported, 43 were murders, 178 were rape/sexual assaults 458 were robberies, and 1,118 were aggravated assaults. Property crimes included burglaries which accounted for 1,191, larcenies for 9,018, and Motor vehicle theft accounted for 1,283 incidents out of the total.
=== Blood tests === When RA is clinically suspected, a physician may test for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs measured as anti-CCP antibodies). The test is positive approximately two-thirds of the time, but a negative RF or CCP antibody does not rule out RA; rather, the arthritis is called seronegative, which occurs in approximately a third of people with RA. During the first year of illness, rheumatoid factor is more likely to be negative with some individuals becoming seropositive over time. RF is a non-specific antibody and seen in about 10% of healthy people, in many other chronic infections like hepatitis C, and chronic autoimmune diseases such as Sjögren's disease and systemic lupus erythematosus. Therefore, the test is not specific for RA. Hence, new serological tests check for anti-citrullinated protein antibodies ACPAs. These tests are again positive in 61–75% of all RA cases, but with a specificity of around 95%. As with RF, ACPAs are many times present before symptoms have started. The by far most common clinical test for ACPAs is the anti-cyclic citrullinated peptide (anti CCP) ELISA. In 2008, a serological point-of-care test for the early detection of RA combined the detection of RF and anti-MCV with a sensitivity of 72% and specificity of 99.7%. To improve the diagnostic capture rate in the early detection of patients with RA and to risk-stratify these individuals, the rheumatology field continues to seek complementary markers to both RF and anti-CCP.
=== Acute toxicity === Melamine is reported to have an oral median lethal dose (LD50) of 3248 mg/kg based on rat data. It is also an irritant when inhaled or in contact with the skin or eyes. The reported dermal LD50 is greater than 1000 mg/kg for rabbits. A study by Soviet researchers in the 1980s suggested that melamine cyanurate, commonly used as a fire retardant, could be more toxic than either melamine or cyanuric acid alone. For rats and mice, the reported LD50 for melamine cyanurate was 4.1 g/kg (given inside the stomach) and 3.5 g/kg (via inhalation), compared to 6.0 and 4.3 g/kg for melamine and 7.7 and 3.4 g/kg for cyanuric acid respectively. A toxicology study in animals conducted after recalls of contaminated pet food concluded that the combination of melamine and cyanuric acid in diet does lead to acute kidney injury in cats. A 2008 study produced similar experimental results in rats and characterized the melamine and cyanuric acid in contaminated pet food from the 2007 outbreak. A 2010 study from Lanzhou University attributed kidney failure in humans to uric acid stone accumulation after ingestion of melamine resulting in a rapid aggregation of metabolites such as cyanuric acid diamide (ammeline) and cyanuric acid. A 2013 study demonstrated that melamine can be metabolized to cyanuric acid by gut bacteria. In particular, Klebsiella terrigena was determined to be a factor in melamine toxicity. In culture, K. terrigena was shown to convert melamine to cyanuric acid directly.
== Corneal epithelial cells == Corneal epithelial cells present a physical barrier to prevent microbes from reaching the interior of the eye chamber, which is effectively separated from the rest of the body via tight junctions. At the same time, corneal epithelial cells also secrete cytokines to activate microbial defense. One cytokine, interleukin (IL)-1α, is stored in epithelial cells and automatically released when the cell membrane is ruptured by infection or trauma. However, long-term effects of IL-1α can lead to not only enhanced immune infiltration of the cornea, but also neovascularization (formation of new blood vessels), which can lead to a loss of corneal transparency. Therefore, the cornea has also been found to secrete an IL-1α antagonist, IL-1RN, which decreases leucocyte invasion of the cornea and suppresses neovascularization, both of which can help preserve vision.
Sources: en.wikipedia.org
In spite of these warnings, the Luftwaffe did little to address this and treated the entire topic with some level of disdain. Their own radars were superior to CH in many ways, but had proven to be only marginally useful. During the Air Battle of the Heligoland Bight in 1939, a German Freya radar detected the raid while it was still an hour away from its target, yet had no way to report this to any of the fighter units that could intercept it. Getting the information from the radar to the pilots in a useful form appeared to be a difficult problem, and the Germans believed the British would have the same difficulty and thus radar would have little real effect. Some desultory effort was put into attacking the CH stations, especially during the opening stages of the Battle. British engineers were able to quickly return these units to service, or in some cases simply pretend to do so in order to fool the Germans into thinking the attacks failed. As the pattern of these attacks became clear, the RAF began to counter them with increasing effectiveness. The Junkers Ju 87 dive bombers were subjected to catastrophic losses and had to be withdrawn from battle. The Germans gave up trying to attack CH directly on any reasonable scale. Thus, CH was allowed to operate throughout the Battle largely unhindered. Although communications were indeed a serious problem, it was precisely this problem that the Dowding system had been set up to address, at great expense. The result was that every British fighter was roughly twice or perhaps more as effective than its German counterpart.
==== Quantities required ==== A rule of thumb for dry ice bath branding states that twenty pounds (9.1 kg) of dry ice and three US gallons (11 L) of 99% alcohol are sufficient to freeze-brand one hundred head of cattle inside a three to four-hour period. An entire day of freeze branding may consume 50–75 pounds (23–34 kilograms) of dry ice and six to nine US gallons (23 to 34 L) of ethanol. The dry ice should be broken up into egg-sized pieces, placed in a styrofoam container or styrofoam-insulated metal cooler and covered with at least three inches (7.6 cm) of alcohol. Many consumer coolers are made from plastics that become exceptionally brittle at cryogenic temperatures. This is a safety concern if heavy metal brands are frequently returned to coolant baths because 99% alcohol is extremely flammable. Insulated aluminum containers are preferred.
Hypoglycemia Epinephrine (via β2, α2, and α1 adrenergic receptors) Arginine Alanine (often from muscle-derived pyruvate/glutamate transamination (see alanine transaminase reaction). Acetylcholine Cholecystokinin Gastric inhibitory polypeptide Gastrin Secretion of glucagon is inhibited by:
== Mode of action classification == IRAC publishes an insecticide mode of action (MoA) classification that lists most common insecticides and acaricides and recommends that "successive generations of a pest should not be treated with compounds from the same MoA Group". IRAC assigns a mode of action (MoA) to an insecticide, based on sufficient scientific data. They then update the mode of action (MoA) classification. Several insecticides and classes of insecticide may act through the same mode of action.
=== Primary cold agglutinin disease === In single-center series, primary CAD has been found to account for 13–15% of the cases of AIHA. In a population-based clinical study of primary CAD in Norway, the prevalence was found to be 16 per million in habitants and the incidence rate 1 per million inhabitants per year. Little is known about possible geographic variations. Median age of CAD patients was 76 years and median age at onset of symptoms was approximately 67 years. The male/female ratio has been reported to be 0.5–0.6 which is not very different from a male/female ratio of 0.72 in an age-matched general population. The frequency of auto-immune disorders other than CAD does probably not differ from what is to be expected in an elderly population with some female predominance. as about 12.5 years from diagnosis and median age at death was 82 years, which implies a life expectancy in these patients similar to that of an age-matched general population. More than 90% of patients with primary CAD have Cold-induced circulatory symptoms ranging from moderate acrocyanosis to severe Raynaud phenomena precipitated even by very slight cold exposure.
Sources: en.wikipedia.org
Bacteria have the relatively well-known secretion systems that can inject a payload (possibly a toxin) into another cell. Pseudomonas aeruginosa, for example, use a type VI secretion system to target competing microbes. The injection mechanism of bacteriophages is arguably similar to a venom. Stinging plants deliver toxins into targets. There are also more active mechanisms such as the haustorium of Cuscuta, injecting digestive enzymes to facilitate extration of nutrients. Phytopathogenic fungi use appressoria to penetrate target plants and deliver cell-killing toxins. Entomopathogenic fungi may also use appressoria to penetrate insects. Nematophagous fungi use many mechanisms to capture and penetrate the target nematode. They also produce toxins. Among protists, Coleps use specialized organelles called toxicysts to inject toxins into prey. Other protists may use extrusomes.
Clinical endpoints can be obtained from different modalities, such as behavioural or cognitive scores, or biomarkers from Electroencephalography (qEEG), MRI, PET, or biochemical biomarkers. In clinical cancer research, common endpoints include discovery of local recurrence, discovery of regional metastasis, discovery of distant metastasis, onset of symptoms, hospitalization, increase or decrease in pain medication requirement, onset of toxicity, requirement of salvage chemotherapy, requirement of salvage surgery, requirement of salvage radiotherapy, death from any cause, or death from disease. A cancer study may be powered for overall survival, usually indicating time until death from any cause, or disease-specific survival, where the endpoint is death from disease or death from toxicity. These are expressed as a period of time (survival duration) e.g., in months. Frequently the median is used so that the trial endpoint can be calculated once 50% of subjects have reached the endpoint, whereas calculation of an arithmetical mean can only be done after all subjects have reached the endpoint.
The final judgement described the actions of the pilots as ‘reprehensible’, increased the penalty to disqualification and removed their flights from the competition record. The Appeal Tribunal also recommended the FAI to take further disciplinary action against those involved. Following the Tribunals verdict Lisa Turner (the Australian pilots’ representative to the tribunal) issued a press release re-iterating their denial of cheating, accused the tribunal of bias against the Australian team and announced a further appeal to the Court of Arbitration for Sport CAS.
Lysergic acid diethylamide, commonly known as LSD (from German Lysergsäurediethylamid) and by the nicknames acid and Lucy, is a semisynthetic psychedelic drug derived from ergot, known for its potent psychological effects. LSD taken orally has an onset of action of 0.4 to 1.0 hours and a duration of 7 to 12 hours. In recreational settings it is commonly administered via tabs of blotter paper. LSD is extremely potent, with noticeable effects at doses as low as 20 micrograms and is sometimes taken in even smaller amounts for microdosing. Despite widespread use, no fatal human overdoses have been documented. LSD is mainly used recreationally or for spiritual purposes. LSD can cause mystical experiences. LSD exerts its effects primarily through high-affinity binding to several serotonin receptors, especially the serotonin 5-HT2A receptor, and to a lesser extent dopamine and adrenergic receptors. Neuroimaging studies indicate that LSD reduces the efficacy of thalamo-cortical information filtering (producing sensory overload), decreases oscillatory power within the default mode network, and flattens hierarchical organization of large-brain activity. At higher doses, it can induce visual and auditory hallucinations, ego dissolution, and anxiety. LSD use can cause hallucinogen-induced psychotic disorder where paranoia and delusions persist beyond the initial effects of the drug. LSD may lead to persistent visual disturbances known as hallucinogen persisting perception disorder (HPPD).
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.